Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando L Pagan

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|June 6, 2022
Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodiesFernando L Pagan, Yasar Torres-Yaghi, Michaeline L Hebron, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 14, 2021
Combination targeting of subthalamic nucleus and ventral intermediate thalamic nucleus with a single trajectory in deep brain stimulation for tremor-dominant Parkinson's diseaseIslam Fayed, Kelsey D Cobourn, Gnel Pivazyan, et al.
Neurology. Genetics|November 17, 2021
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson DiseaseAlan J Fowler, Jaeil Ahn, Michaeline Hebron, et al.
Neurology. Clinical Practice|March 1, 2017
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapyAlberto J Espay, Fernando L Pagan, Benjamin L Walter, et al.
American Journal of Physical Medicine & Rehabilitation|August 24, 2016
A Screening Tool to Identify Spasticity in Need of TreatmentRichard D Zorowitz, Theodore H Wein, Kari Dunning, et al.
Neurology and Therapy|January 18, 2023
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson's DiseaseMichael J Soileau, Fernando L Pagan, Alfonso Fasano, et al.
Human Molecular Genetics|August 11, 2020
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseasesAlan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Pharmacology Research & Perspectives|March 26, 2019
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's diseaseFernando L Pagan, Michaeline L Hebron, Barbara Wilmarth, et al.
JAMA Neurology|December 17, 2019
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical TrialFernando L Pagan, Michaeline L Hebron, Barbara Wilmarth, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|January 12, 2026
Underlying Tremor Improvement with Consistent Use of Transcutaneous Afferent Patterned Stimulation in Patients with Essential TremorStuart H Isaacson, Elizabeth Peckham, Winona Tse, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Alzheimer'S & Dementia (New York, N. Y.)|June 6, 2022
Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodiesFernando L Pagan, Yasar Torres-Yaghi, Michaeline L Hebron, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|February 14, 2021
Combination targeting of subthalamic nucleus and ventral intermediate thalamic nucleus with a single trajectory in deep brain stimulation for tremor-dominant Parkinson's diseaseIslam Fayed, Kelsey D Cobourn, Gnel Pivazyan, et al.
Neurology. Genetics|November 17, 2021
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson DiseaseAlan J Fowler, Jaeil Ahn, Michaeline Hebron, et al.
Neurology. Clinical Practice|March 1, 2017
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapyAlberto J Espay, Fernando L Pagan, Benjamin L Walter, et al.
American Journal of Physical Medicine & Rehabilitation|August 24, 2016
A Screening Tool to Identify Spasticity in Need of TreatmentRichard D Zorowitz, Theodore H Wein, Kari Dunning, et al.
Neurology and Therapy|January 18, 2023
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson's DiseaseMichael J Soileau, Fernando L Pagan, Alfonso Fasano, et al.
Human Molecular Genetics|August 11, 2020
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseasesAlan J Fowler, Michaeline Hebron, Kaluvu Balaraman, et al.
Pharmacology Research & Perspectives|March 26, 2019
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's diseaseFernando L Pagan, Michaeline L Hebron, Barbara Wilmarth, et al.
JAMA Neurology|December 17, 2019
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical TrialFernando L Pagan, Michaeline L Hebron, Barbara Wilmarth, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|January 12, 2026
Underlying Tremor Improvement with Consistent Use of Transcutaneous Afferent Patterned Stimulation in Patients with Essential TremorStuart H Isaacson, Elizabeth Peckham, Winona Tse, et al.
Pageof 3